Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5063148_CN63148_0